Interleukin-15 gene therapy and the mammalian target of rapamycin inhibitor everolimus inhibit the growth of metastatic breast cancer

2013 ◽  
Vol 15 (10) ◽  
pp. 366-374 ◽  
Author(s):  
Na Zhao ◽  
Xiaodan Li ◽  
Xianghui He ◽  
Yujie Qiu ◽  
Liwei Zhu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Therapy ◽  
Metastatic Breast Cancer ◽  
Mammalian Target Of Rapamycin ◽  
Metastatic Breast ◽  
Target Of Rapamycin ◽  
Interleukin 15

scholarly journals Systemic RALA/iNOS Nanoparticles: A Potent Gene Therapy for Metastatic Breast Cancer Coupled as a Biomarker of Treatment

2017 ◽  
Vol 6 ◽  
pp. 249-258 ◽  
Author(s):  
Cian M. McCrudden ◽  
John W. McBride ◽  
Joanne McCaffrey ◽  
Ahlam A. Ali ◽  
Nicholas J. Dunne ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Therapy ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast

scholarly journals Combination of local, nonviral IL12 gene therapy and systemic paclitaxel treatment in a metastatic breast cancer model

2004 ◽  
Vol 9 (6) ◽  
pp. 829-836 ◽  
Author(s):  
Margit Maria Janát-Amsbury ◽  
James W Yockman ◽  
Minhyung Lee ◽  
Steven Kern ◽  
Darin Y Furgeson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Therapy ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Cancer Model ◽  
Breast Cancer Model ◽  
Paclitaxel Treatment

Nitric oxide synthase gene therapy: A potent therapeutic in metastatic breast cancer

Nitric Oxide ◽  
2014 ◽  
Vol 42 ◽  
pp. 111
Author(s):  
Cian McCrudden ◽  
John McBride ◽  
Jonathan Coulter ◽  
Victoria Kett ◽  
Tracy Robson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Nitric Oxide ◽  
Gene Therapy ◽  
Metastatic Breast Cancer ◽  
Nitric Oxide Synthase ◽  
Metastatic Breast ◽  
Oxide Synthase

scholarly journals Mammalian Target of Rapamycin (mTOR) Inhibitors Induce Stomatitis in Patients with Metastatic Breast Cancer (Review)

2020 ◽  
Vol 10 (01) ◽  
pp. 136-140
Author(s):  
Furqan M. Abdulelah ◽  
Hassanien S. Taghi ◽  
Hayder R. Abdulbaqi ◽  
Mustafa R. Abdulbaqi
Keyword(s):  
Breast Cancer ◽  
Health Care ◽  
Metastatic Breast Cancer ◽  
Oral Health ◽  
Cancer Patients ◽  
Mtor Inhibitor ◽  
Mammalian Target Of Rapamycin ◽  
Metastatic Breast ◽  
Oral Health Care ◽  
Breast Cancer Patients

Metastatic breast cancer patients may acquire oral morbidity from therapeutic procedures. A common adverse event (AE) of the Mammalian target of rapamycin (mTOR) inhibitor is associated stomatitis (mIAS) secondary to mTOR inhibitor therapy, which have a negative impact on the quality of life, therapy adherence and health care expenses. A multidisciplinary team strategy is essential for reducing mIAS and capitalize on therapy advantages for breast cancer patients. We discuss the pathophysiology, diagnosis, and natural history of mIAS in this review. In the context of promoting a coordinated team care approach to optimizing patient care, current and new management policies are outlined for the prevention and treatment of mIAS. Types of Studies Reviewed: We piloted different research from 2007 through 2019 using the terms “stomatitis,” “mIAS,” “mTOR,” “everolimus,” “oral care.” and “metastatic breast cancer,” We have chosen papers from peer-reviewed journals reporting controlled trials and evidence-based guidance. Results: Cytototoxic chemical or radiation therapy causes, clinical presentation, and paradigms of therapy can distinguish mIAS from mucositis. The continuum of patient oral health care may include specific preventive and therapeutic leadership approaches. Practical consequences: Oral health providers are at the forefront of oral health care for patients who have metastatic breast cancer and are uniquely positioned to deliver patient education, to advocate precise reporting of mIAS, and to encourage early identification, monitoring and rapid intervention to reduce the serious and time-limiting dose of this manageable AE.

scholarly journals Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102

2018 ◽  
Vol 36 (16) ◽  
pp. 1556-1563 ◽  
Author(s):  
Noah Kornblum ◽  
Fengmin Zhao ◽  
Judith Manola ◽  
Paula Klein ◽  
Bhuvaneswari Ramaswamy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Objective Response ◽  
Mammalian Target Of Rapamycin ◽  
Growth Factor Receptor ◽  
Metastatic Breast ◽  
Progression Free Survival ◽  
Free Survival ◽  
Er Positive ◽  
Epidermal Growth

Purpose The mammalian target of rapamycin inhibitor everolimus targets aberrant signaling through the PI3K/AKT/mammalian target of rapamycin pathway, a mechanism of resistance to anti-estrogen therapy in estrogen receptor (ER)–positive breast cancer. We hypothesized that everolimus plus the selective ER downregulator fulvestrant would be more efficacious than fulvestrant alone in ER-positive metastatic breast cancer resistant to aromatase inhibitor (AI) therapy. Patients and Methods This randomized, double-blind, placebo-controlled, phase II study included 131 postmenopausal women with ER-positive, human epidermal growth factor receptor 2–negative, AI-resistant metastatic breast cancer randomly assigned to fulvestrant (500 mg days 1 and 15 of cycle 1, then day 1 of cycles 2 and beyond) plus everolimus or placebo. The study was designed to have 90% power to detect a 70% improvement in median progression-free survival from 5.4 months to 9.2 months. Secondary end points included objective response and clinical benefit rate (response or stable disease for at least 24 weeks). Prophylactic corticosteroid mouth rinses were not used. Results The addition of everolimus to fulvestrant improved the median progression-free survival from 5.1 to 10.3 months (hazard ratio, 0.61 [95% CI, 0.40 to 0.92]; stratified log-rank P = .02), indicating that the primary trial end point was met. Objective response rates were similar (18.2% v 12.3%; P = .47), but the clinical benefit rate was significantly higher in the everolimus arm (63.6% v 41.5%; P = .01). Adverse events of all grades occurred more often in the everolimus arm, including oral mucositis (53% v 12%), fatigue (42% v 22%), rash (38% v 5%), anemia (31% v. 6%), diarrhea (23% v 8%), hyperglycemia (19% v 5%), hypertriglyceridemia (17% v 3%), and pneumonitis (17% v 0%), although grade 3 to 4 events were uncommon. Conclusion Everolimus enhances the efficacy of fulvestrant in AI-resistant, ER-positive metastatic breast cancer.

Sign in / Sign up

Export Citation Format

Share Document